A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe

Fremanezumab (AJOVY; Teva Pharmaceutical Industries Ltd, Netanya, Israel), approved for the preventive treatment of migraine, is available as a subcutaneous injection either once a month or once every 3 months using an autoinjector or a prefilled syringe. The present study evaluated the pharmacokine...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherniakov, Irina, Cohen‐Barak, Orit, Tiver, Ryan, Gillespie, Michael, Kessler, Yoel, Gutierrez, Maria, Rasamoelisolo, Michele, Li, Shawn, Shen, Honglue, Hallak, Hussein, Loupe, Pippa S., Smith, Michael, Rabinovich‐Guilatt, Laura, Spiegelstein, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451805/
https://www.ncbi.nlm.nih.gov/pubmed/33411992
http://dx.doi.org/10.1002/cpdd.902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451805/
https://www.ncbi.nlm.nih.gov/pubmed/33411992
http://dx.doi.org/10.1002/cpdd.902

Ejemplares similares